UCB psoriasis candidate headed for Phase III

UCB S.A. (Euronext:UCB) said bimekizumab (UCB4940) led to 90% clearance of plaque psoriasis per the Psoriasis Area and Severity Index (PASI 90) in up to 79% of patients in the Phase IIb BE ABLE study, meeting the trial’s primary endpoint.

The company is planning Phase III testing of the candidate. Spokesperson Andrea Christopher declined to give a timeline. UCB plans to publish complete data from the Phase II study early next year...